2-chloro-6-fluorobenzaldehyde

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1987

Report date:

1987

Materials and methods

Test guideline

Test guideline 1

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Version / remarks:

1981

Test guideline 2

Qualifier:

according to guideline

Guideline:

EU Method B.1 (Acute Toxicity (Oral))

Version / remarks:

1984

GLP compliance:

yes (incl. QA statement)

Test type:

acute toxic class method

Limit test:

no

Test material

Test material information

impurity 1

Reference substance name:

2-chloro-6-fluorobenzoic acid

EC Number:

207-105-2

EC Name:

2-chloro-6-fluorobenzoic acid

Cas Number:

434-75-3

Molecular formula:

C7H4ClFO2

IUPAC Name:

2-chloro-6-fluorobenzoic acid

Constituent 1

Reference substance name:

2-chloro-6-fluorobenzaldehyde

EC Number:

206-860-5

EC Name:

2-chloro-6-fluorobenzaldehyde

Cas Number:

387-45-1

Molecular formula:

C7H4ClFO

IUPAC Name:

2-chloro-6-fluorobenzaldehyde

Test material form:

solid: crystalline

Test animals

Species:

rat

Strain:

Wistar

Sex:

male/female

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

other: Sesame oil

Doses:

3150, 4000, 5000 mg/kg

No. of animals per sex per dose:

5

Results and discussion

Effect levels

Effect levels 1

Key result

Sex:

male/female

Dose descriptor:

LD50

Effect level:

4 110 mg/kg bw

Based on:

test mat.

95% CL:

3 460 - 5 120

Effect levels 2

Key result

Sex:

female

Dose descriptor:

LD50

Effect level:

3 880 mg/kg bw

Based on:

test mat.

95% CL:

2 580 - 5 400

Effect levels 3

Key result

Sex:

male

Dose descriptor:

LD50

Effect level:

4 360 mg/kg bw

Based on:

test mat.

95% CL:

3 310 - 7 350

Mortality:

Male:
3 of 5 died in the 4000 mg/kg and 5000 mg/kg group. No animal died at 3150 mg/kg.
Female:
1 died in the 3150 mg/kg group.
3 of 5 died in the 4000 mg/kg and 5000 mg/kg group

Clinical signs:

other: The following clinical symptoms were observed in male and female animals: reduced spontaneous activity, drawn-in flanks, crouching position, uncoordinated, staggering and long-legged gait, forward movement in a crawling position, ruffled fur, drowsiness,

Gross pathology:

The macroscopic examination of the dead male and female animals showed bleeding of the gastric inner wall, clearly injected blood vessels in the area of the gastrointestinal tract, greatly reduced and hardened appendix as well as partial to complete lightening of the liver, kidneys and spleen.
The animals killed at the end of the observation period were free from macroscopically visible changes.

Applicant's summary and conclusion

Interpretation of results:

Category 5 based on GHS criteria

Conclusions:

According to REGULATION (EC) No 1272/2008 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 2008 the test substance does not fulfil the criteria for classification as acute toxic.
According to UN-GHS, 8th revision, the substance should be classfied as acute toxic (oral route) category 5